Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 20/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 19/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.72 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.71 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261648 | 0.94 | OPRD1 (0.71) | OPRD1KCNH2CYP2D6OPRK1MRGPRX2 | |
| SCHEMBL12261655 | 0.92 | OPRD1 (0.73) | OPRD1KCNH2CYP2D6OPRK1MRGPRX2 | |
| SCHEMBL467384 | 0.92 | OPRD1 (0.73) | OPRD1KCNH2CYP2D6OPRK1MRGPRX2 | |
| SCHEMBL10258700 | 0.90 | OPRD1 (0.70) | OPRD1KCNH2CYP2D6OPRK1MRGPRX2 | |
| SCHEMBL10257905 | 0.90 | OPRD1 (0.69) | OPRD1KCNH2CYP2D6OPRK1MRGPRX2 | |
| SCHEMBL10258250 | 0.89 | OPRD1 (0.74) | OPRD1KCNH2CYP2D6OPRK1MRGPRX2 | |
| SCHEMBL10258170 | 0.89 | OPRD1 (0.77) | OPRD1KCNH2CYP2D6OPRK1MRGPRX2 | |
| SCHEMBL467126 | 0.88 | OPRD1 (0.67) | OPRD1KCNH2CYP2D6OPRK1MRGPRX2 | |
| SCHEMBL10258389 | 0.88 | OPRD1 (0.75) | OPRD1KCNH2CYP2D6OPRK1MRGPRX2 | |
| SCHEMBL10258247 | 0.88 | OPRD1 (0.70) | OPRD1KCNH2CYP2D6OPRK1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110218186-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218186-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | OPRD1 2/4885KCNH2 1285/4885CYP2D6 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.